Vyome announces Nasdaq approval of merger with ReShape Lifesciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 13 2025
0mins
Merger and Listing Approval: Vyome Therapeutics has received approval from The Nasdaq Stock Market for its listing following the merger with ReShape Lifesciences, set to take effect on August 15 under the name Vyome Holdings, Inc. and trading symbol "HIND."
Focus on Shareholder Value: Chairman Krishna Gupta emphasized the company's commitment to shareholder value and innovation in the healthcare market, inviting RSLS shareholders and others to join their journey.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
